01
Molecular liability
A governed molecular liability can reduce benchmark PoS and change the final Monte Carlo rNPV.
Molecule -> PoS -> rNPV
Supported by
Ecosystem and memberships
What decision-active means
A change in the science can change the model and the action.
02
Molecular similarity
Molecular similarity can become a portfolio correlation assumption, changing covariance, diversification and capital allocation.
Similarity -> correlation -> allocation
03
Safety evidence
A serious safety liability remains a hard veto. It cannot disappear inside an attractive average score.
Safety signal -> veto -> defer or stop
04
Target evidence
Target biology, contradictory evidence, coverage and safety can change an advance, defer or stop posture.
Target case -> decision posture
05
Indication evidence
Target validation, pathway enrichment, druggability, assay quality and ADMET readiness can change feasibility and sequence.
Evidence -> feasibility -> sequence
06
Scientific uncertainty
EVPI, EVPPI and EVSI compare the value of resolving uncertainty with the cost and timing of the experiment.
Uncertainty -> information value -> experiment
Six Studios. One system.
Use the science required by the decision.
Each Studio applies a defined biopharma method to a specific decision. A Decision Case can use one Studio or several, while evidence, assumptions and asset context remain connected between them.
Explore StudiosStudios are introduced through private enterprise engagements. Available methods depend on the decision, deployment configuration and permitted evidence.
01
Target opportunity
Target Studio
Does this target deserve the next investment?
Assemble target identity, disease biology, mechanism, tractability, safety and clinical precedent. ARiDA shows which evidence strengthens the thesis, which evidence blocks it and what should be learned next.
Open Target02
Asset decisions
Drug Studio
Should this asset advance, defer, stop, be licensed or be passed?
Keep molecular developability, mechanism, clinical evidence, safety, competitive analogues, regulatory context, IP evidence and business assumptions inside the same asset case.
Open Drug03
Expansion strategy
Indication Studio
Where should this asset go next?
Compare scientific admissibility, clinical feasibility, differentiation, economics and execution constraints without hiding a weak dimension inside one composite score.
Open Indication04
Asset and portfolio value
Valuation Studio
What is the defensible value range, and what moves it?
Connect scientific and clinical assumptions to rNPV, Monte Carlo distributions, real options and value of information. Reviewers can inspect an assumption and rerun the affected case.
Open Valuation05
Capital allocation
Portfolio Studio
Which programs should receive capital now?
Evaluate assets against strategy, cash, capacity, shared scientific risk, timing and available options. Keep credible alternatives and dominated choices visible for the committee.
Open Portfolio06
IP evidence
Patent Studio
Which IP evidence changes the business decision?
Connect patent-family, ownership, claim-theme, exclusivity and proceeding evidence to lifecycle, transaction and competitive questions. Patent Studio prepares evidence for business and counsel review. It does not provide legal opinions or clearance conclusions.
Open PatentDecision Cases and Asset 360
Keep the scientific case and the business decision together.
A Decision Case preserves the question, exact asset revision, evidence state, assumptions, methods, alternatives, dissent, selected action, approvals and reopening triggers. Asset 360 carries the scientific and commercial context between Studios.
One durable record
See the model move when the evidence changes.
Supported objects can recompute from a reviewed assumption change. The case keeps the prior value, new value, affected calculation and reason for the change available to reviewers.
Question and revision
The case identifies the decision and the exact asset state under review.
Method and alternatives
Assumptions, computations, hard gates and credible alternatives remain inspectable.
Release and reopening
Approvals, dissent, actions and the evidence that should reopen the case stay recorded.
Frame the case
Define the decision before the research expands.
ARiDA records the alternatives, decision criteria, evidence requirements and unresolved questions before a Studio starts work. The case then gathers and computes only what the decision requires.
Review and release
Keep the recommendation attached to its basis.
Reviewers can inspect evidence, assumptions, calculations, alternatives and dissent before approving a release. Reopening triggers record what new evidence or threshold should bring the decision back to the team.
Decision outputs
The analysis should show what changed and why.
Review the scientific input, the affected calculation, the resulting decision question and the limits of the analysis. Selected outputs can be released as workbooks, memos, decks or structured records without losing the assumptions behind them.
Stage-gated rNPV
- Scientific or business input
- Development timing, cost, revenue and probability assumptions, including supported scientific adjustments.
- Calculation or analytical consequence
- Risk-adjusted cash flows and stage transitions across the program.
- Decision question
- Which value drivers and assumptions deserve challenge before the asset moves forward?
Release formats
Move reviewed work into the format the next reviewer needs.
Files are the release and handoff format, not the product itself. The Decision Case remains the record of the evidence, assumptions, calculation and approval behind each exported view.
PPTX
Committee decks
Reviewed charts and conclusions arranged for a decision meeting.
- Investment committee deck
- Business development review
- Asset decision readout
XLSX
Working models
Formulas, assumptions and sensitivities available for finance review.
- rNPV assumption model
- Portfolio allocation workbook
- Scenario register
PDF
Released reports
A stable record of the analysis, caveats and approved recommendation.
- Decision memo with appendix
- Scientific assessment
- Asset dossier
DOCX
Editable narratives
Working copy for subject-matter and editorial review.
- Pre-meeting brief
- Strategic options memo
- Development recommendation
MD · JSON · CSV
Structured handoffs
Machine-readable records for approved downstream use.
- Markdown for the knowledge base
- JSON for an internal system
- CSV for further analysis
The computational spine
ARiDA carries science into the business decision.
Evidence passes through a defined scientific method, into the relevant calculation and onward to a recorded choice. These four layers explain how the recommendation can change without losing its basis.
01
Scientific engines
Methods that understand the evidence entering the decision.
Molecular descriptors, similarity, target biology, pathway evidence, clinical precedent, safety and other scientific inputs are handled by defined methods with explicit gaps and provenance.
Decision consequence
A liability, contradiction or stronger biological case can change the inputs used by the business model.
02
Decision mathematics
The scientific input reaches the calculation that leadership uses.
PoS, Monte Carlo rNPV, covariance, portfolio allocation, real options and value of information run as inspectable calculations rather than manually re-entered conclusions.
Decision consequence
The value range, downside, diversification case or next-experiment economics move with the evidence.
03
Decision rules and hard gates
Blocking evidence stays blocking.
Safety vetoes, admissibility rules, missing-data behavior, thresholds and scenario assumptions remain explicit. A strong score elsewhere cannot silently cancel a serious liability.
Decision consequence
The recommended action can move from advance to defer or stop, with the triggering rule visible.
04
Decision memory
A later review begins from the prior decision, not a reconstructed deck.
Decision Cases preserve the asset revision, evidence state, assumptions, alternatives, dissent, selected action, approvals, release history and reopening triggers.
Decision consequence
New evidence can be compared with the approved baseline and routed back to the responsible team.
Evidence substrate
The evidence stays connected to the decision it informs.
ARiDA relates evidence to assets, targets, mechanisms, trials, assumptions and prior decisions. Sources remain inspectable, but they are inputs to the scientific and business method rather than the product story itself.
Decision continuity
A decision should not lose its history when the evidence changes.
ARiDA keeps monitoring, review and follow-up connected to the original Decision Case. Teams can compare a new result with the approved baseline and see why the case reopened.
Review where the team works
Web
Review the full Decision Case and its working material.Microsoft Teams
Bring case updates into the team workspace.Email
Receive scheduled reviews and respond in context.Telegram
Handle concise updates and approvals while away from the desk.Return new evidence to the case
A material paper, trial update, safety finding or competitor event is attached to the Decision Case it may change, not dropped into a separate feed.
Compare against the approved baseline
ARiDA preserves the prior evidence state, assumptions and result. The team can see what changed before accepting a new recommendation.
Reopen on explicit terms
Reopening triggers can be tied to scientific, clinical, commercial or execution conditions. A case returns for review when one of those conditions is met.
Keep external action approval-led
Scheduled work and channel delivery can continue in the background. Messages, releases and consequential actions remain subject to the configured approval policy.
Evaluate continuity against a decision your team already reviews.
Security and compliance
Built for demanding biopharma teams with security, compliance and reliability at enterprise scale.
Enterprise controls
A recommendation should survive inspection.
Each Decision Case records the evidence, assumptions, calculation, method version, unresolved gaps, approvals and release history behind the recommendation. When evidence is missing, the case records the gap and shows how it limits the decision.
Enterprise evaluation includes a review of deployment architecture, access controls, data handling, source rights and retention configuration.
- Scoped workspaces and role-gated access
- Source and assumption lineage
- Versioned compute records and artifact hashes
- Approval and release gates
- Spend controls and audited run state
- Separate internal work and released stakeholder views
Enterprise engagements
Bring us a decision that matters now.
Start with the asset, portfolio or transaction your team must review. We will map the scientific method, decision model, evidence rights, controls and deployment needed to run the case in ARiDA.
Frequently asked questions.
ARiDA connects scientific analysis to the calculations and choices used in biopharma development, valuation and portfolio work. It keeps the question, evidence, assumptions, model, alternatives and resulting decision in one durable Decision Case.